These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

307 related items for PubMed ID: 12140145

  • 1. Phase I study of weekly CPT-11 (irinotecan)/docetaxel in patients with advanced solid tumors.
    Font A, Sanchez JM, Rosell R, Taron M, Martinez E, Guillot M, Manzano JL, Margeli M, Barnadas A, Abad A.
    Lung Cancer; 2002 Aug; 37(2):213-8. PubMed ID: 12140145
    [Abstract] [Full Text] [Related]

  • 2. A dose-escalation study of irinotecan (CPT-11) in combination with cisplatin in patients with advanced non-small cell lung cancer previously treated with a docetaxel-based front line chemotherapy.
    Kakolyris S, Souglakos J, Agelaki S, Kourousis CH, Mavroudis D, Sarra E, Malliotakis P, Georgoulias V.
    Lung Cancer; 2000 Dec; 30(3):193-8. PubMed ID: 11137204
    [Abstract] [Full Text] [Related]

  • 3. Phase I study of carboplatin, irinotecan and docetaxel on a divided schedule with recombinant human granulocyte colony stimulating factor support in patients with stage IIIB or IV non-small cell lung cancer.
    Fujita A, Ohkubo T, Hoshino H, Takabatake H, Tagaki S, Sekine K.
    Anticancer Drugs; 2002 Jun; 13(5):505-9. PubMed ID: 12045462
    [Abstract] [Full Text] [Related]

  • 4. Phase I and pharmacologic study of docetaxel and irinotecan in advanced non-small-cell lung cancer.
    Masuda N, Negoro S, Kudoh S, Sugiura T, Nakagawa K, Saka H, Takada M, Niitani H, Fukuoka M.
    J Clin Oncol; 2000 Aug; 18(16):2996-3003. PubMed ID: 10944133
    [Abstract] [Full Text] [Related]

  • 5. Phase I dose escalation trial of weekly docetaxel plus irinotecan in patients with advanced cancer.
    Bleickardt E, Argiris A, Rich R, Blum K, McKeon A, Tara H, Zelterman D, Burtness B, Davies MJ, Murren JR.
    Cancer Biol Ther; 2002 Aug; 1(6):646-51. PubMed ID: 12642688
    [Abstract] [Full Text] [Related]

  • 6. A phase I trial of weekly docetaxel and cisplatinum combined to concurrent hyperfractionated radiotherapy for non-small cell lung cancer and squamous cell carcinoma of head and neck.
    Varveris H, Mazonakis M, Vlachaki M, Kachris S, Lyraraki E, Zoras O, Maris T, Froudarakis M, Velegrakis J, Perysinakis C, Damilakis J, Samonis G.
    Oncol Rep; 2003 Aug; 10(1):185-95. PubMed ID: 12469168
    [Abstract] [Full Text] [Related]

  • 7. Phase I trial of outpatient weekly docetaxel, carboplatin and concurrent thoracic radiation therapy for stage III unresectable non-small-cell lung cancer: a Vanderbilt cancer center affiliate network (VCCAN) trial.
    Choy H, DeVore RF, Hande KR, Porter LL, Rosenblatt PA, Slovis B, Laporte K, Shyr Y, Johnson DH.
    Lung Cancer; 2001 Dec; 34(3):441-9. PubMed ID: 11714542
    [Abstract] [Full Text] [Related]

  • 8. Phase I and pharmacokinetic study of docetaxel and irinotecan in patients with advanced solid tumors.
    Couteau C, Risse ML, Ducreux M, Lefresne-Soulas F, Riva A, Lebecq A, Ruffié P, Rougier P, Lokiec F, Bruno R, Armand JP.
    J Clin Oncol; 2000 Oct 15; 18(20):3545-52. PubMed ID: 11032597
    [Abstract] [Full Text] [Related]

  • 9. Salvage treatment of advanced non-small-cell lung cancer previously treated with docetaxel-based front-line chemotherapy with irinotecan (CPT-11) in combination with cisplatin.
    Kakolyris S, Kouroussis C, Kalbakis K, Mavroudis D, Souglakos J, Nvardakis, Kremos S, Georgoulias V.
    Ann Oncol; 2000 Jun 15; 11(6):757-60. PubMed ID: 10942068
    [Abstract] [Full Text] [Related]

  • 10. Phase I and pharmacokinetic study of irinotecan and docetaxel in patients with advanced solid tumors: preliminary evidence of clinical activity.
    Adjei AA, Klein CE, Kastrissios H, Goldberg RM, Alberts SR, Pitot HC, Sloan JA, Reid JM, Hanson LJ, Atherton P, Rubin J, Erlichman C.
    J Clin Oncol; 2000 Mar 15; 18(5):1116-23. PubMed ID: 10694565
    [Abstract] [Full Text] [Related]

  • 11. Phase I study of docetaxel and irinotecan in patients with advanced non-small-cell lung cancer.
    Nogami N, Harita S, Ueoka H, Yonei T, Kiura K, Kamei H, Tabata M, Segawa Y, Gemba K, Tanimoto M.
    Lung Cancer; 2004 Jul 15; 45(1):85-91. PubMed ID: 15196738
    [Abstract] [Full Text] [Related]

  • 12. Weekly chemotherapy with carboplatin, docetaxel and irinotecan in advanced non-small-cell-lung cancer: a phase II study.
    Pectasides D, Visvikis A, Kouloubinis A, Glotsos J, Bountouroglou N, Karvounis N, Ziras N, Athanassiou A.
    Eur J Cancer; 2002 Jun 15; 38(9):1194-200. PubMed ID: 12044505
    [Abstract] [Full Text] [Related]

  • 13. A phase I-II study of bi-weekly gemcitabine and irinotecan as second-line chemotherapy in non-small cell lung cancer after prior taxane + platinum-based regimens.
    Kosmas C, Tsavaris N, Syrigos K, Koutras A, Tsakonas G, Makatsoris T, Mylonakis N, Karabelis A, Stathopoulos GP, Kalofonos HP.
    Cancer Chemother Pharmacol; 2007 Jan 15; 59(1):51-9. PubMed ID: 16622691
    [Abstract] [Full Text] [Related]

  • 14. A phase I study of weekly docetaxel and cisplatin in advanced non-small cell lung cancer.
    Sato K, Tsuchiya S, Minato K, Takei Y, Watanabe S, Saitoh R, Mori M.
    Lung Cancer; 2001 Jul 15; 33(1):69-73. PubMed ID: 11429197
    [Abstract] [Full Text] [Related]

  • 15. [Phase I/II clinical trial of weekly administration of docetaxel plus cisplatin for advanced non-small cell lung cancer].
    Li JL, Zhang XR, Liu JW, Chen ZY, Lin YC, Wang YD, Chen Q, Nan KJ, Song SP, Han FC, Zhu YZ, Li LY, Zheng YH, Chu DT.
    Zhonghua Zhong Liu Za Zhi; 2006 Apr 15; 28(4):309-12. PubMed ID: 16875636
    [Abstract] [Full Text] [Related]

  • 16. Phase I and pharmacologic study of irinotecan and etoposide with recombinant human granulocyte colony-stimulating factor support for advanced lung cancer.
    Masuda N, Fukuoka M, Kudoh S, Matsui K, Kusunoki Y, Takada M, Nakagawa K, Hirashima T, Tsukada H, Yana T.
    J Clin Oncol; 1994 Sep 15; 12(9):1833-41. PubMed ID: 7521905
    [Abstract] [Full Text] [Related]

  • 17. Phase I study of carboplatin, docetaxel and irinotecan with recombinant human granulocyte colony stimulating factor support in patients with advanced non-small cell lung cancer.
    Fujita A, Takabatake H, Tagaki S, Sekine K.
    Anticancer Drugs; 2000 Nov 15; 11(10):821-4. PubMed ID: 11142689
    [Abstract] [Full Text] [Related]

  • 18. Phase I/II study of escalating doses of nedaplatin in combination with irinotecan for advanced non-small-cell lung cancer.
    Oshita F, Yamada K, Kato Y, Ikehara M, Noda K, Tanaka G, Nomura I, Suzuki R, Saito H.
    Cancer Chemother Pharmacol; 2003 Jul 15; 52(1):73-8. PubMed ID: 12750839
    [Abstract] [Full Text] [Related]

  • 19. Biweekly docetaxel-irinotecan with filgrastim support in pretreated breast and non-small-cell lung cancer patients. A phase I study.
    Frasci G, Comella P, Thomas R, Di Bonito M, Lapenta L, Capasso I, Botti G, Vallone P, De Rosa V, D'Aiuto G, Comella G.
    Cancer Chemother Pharmacol; 2004 Jan 15; 53(1):25-32. PubMed ID: 14513281
    [Abstract] [Full Text] [Related]

  • 20. A Phase I/II trial of concurrent docetaxel and radiation after induction chemotherapy in patients with poor prognosis squamous cell carcinoma of the head and neck.
    Tishler RB, Norris CM, Colevas AD, Lamb CC, Karp D, Busse PM, Nixon A, Frankenthaler R, Lake-Willcutt B, Costello R, Case M, Posner MR.
    Cancer; 2002 Oct 01; 95(7):1472-81. PubMed ID: 12237916
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 16.